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Purpose: There are few data regarding the epidemiology of hereditary or familial pros-
tate cancer (PCa) in East Asians, especially in Korean men. Therefore, we evaluated 
the incidence of familial and hereditary PCa and the relation between socioeconomic 
status and the incidence of nonsporadic prostate cancer (NSPC).
Materials and Methods: We collected data from all patients who were treated for PCa 
at our center between November 2009 and January 2010. All patients were either newly 
diagnosed or had been diagnosed with PCa and seen as outpatients during the study 
period. 
Results: In a sample of 218 patients with PCa; 25 (11.5%) were NSPC patients, and 
193 (88.6%) were sporadic PCa sporadic prostate cancer (SPC) patients. Overall, 11.5% 
of the patients had a positive family history. There was one hereditary PCa family (three 
patients, 1.4%) and 11 familial PCa families (22 patients, 10.1%). Patients were divided 
into three different age groups. Of these, 18 (9.3%) SPC patients and 6 (24%) NSPC 
patients were diagnosed with the disease at the age of 55 years or younger (p=0.02). 
Prostate-specific antigen (PSA) levels in the NSPC group were significantly higher than 
in the SPC group (7.2±3.2 versus 6.3±4.9 ng/ml, p=0.042). SPC patients had larger waist 
circumferences than did NSPC patients (p=0.041). There were no significant differ-
ences between the SPC and NSPC groups in terms of socioeconomic status, Gleason 
score, pathological stage, or pathologic Gleason grade. 
Conclusions: East Asian NSPC patients are diagnosed at earlier ages than are SPC 
patients, even though the incidence of NSPC in the East Asian population is lower than 
in Western men. 
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INTRODUCTION 
In recent years, prostate cancer (PCa) has become the most 
common malignancy among men in most Western 
countries. Due to the aging of the population, the absolute 
number of new PCa diagnoses is expected to increase up 
to 64% by the year 2020 [1]. Epidemiological and linkage 
studies have revealed a significant hereditary component 
to PCa [2,3]. Approximately 10% to 20% of patients with 
PCa have a positive family history, which increases the life-
time risk of the disease 2- to 11-fold [2,4]. The risk is highest 
for relatives of patients diagnosed before the age of 60 and 
for those with more than one affected relative. Hereditary 
PCa is typically diagnosed 6 to 7 years earlier than is the 
sporadic form [5]. These findings suggest a potential genet-
ic etiology for the familial aggregation of PCa.
Unfortunately, there are no data regarding either the ep-
idemiology or genetics of hereditary or familial PCa in East 
Asians, especially in Korean men. Most studies have been 
confined to subjects of European descent, and little is 
known about the familial aggregation of PCa in pop-
ulations with a low incidence of disease. Therefore, we eval-
uated the incidences of familial and hereditary PCa among 
Korean outpatients with previously or newly diagnosed Korean J Urol 2011;52:9-12
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TABLE 1. Clinical and pathological characteristics of SPC and 
NSPC patients
SPC NSPC  p-value
No. of patients
BMI
Waist circumference (cm)
Age at diagnosis (yr)
Median
Mean±SD
Follow-up duration from 
diagnosis (yr)
Median
Mean±SD
PSA
Biospy Gleason scores (n)
6 or less 
7 
8 or above 
Pathologic stage
T2N0M0
T3N0M0
Greater than T4N0M0
Primary treatment
Surgery 
Hormonal treatment 
Other treatment 
193
24.8±4.5
87.9±6.9
68
69.1±3.4
 
2.8
  1.4±0.5
  7.2±3.2
  82 (42.5)
  69 (35.8)
  42 (21.8)
146 (75.6)
  45 (23.3)
  2 (1.0)
149 (77.2)
  32 (16.6)
12 (6.2)
19
23.2±3.1
82.8±8.1
66
64.6±4.8
1.7
  1.9±0.7
  6.3±4.9
8 (42.1)
7 (36.8)
4 (21.1)
16 (84.1)
  2 (10.5)
1 (5.2)
13 (68.4)
  5 (26.3)
1 (5.3)
0.082
a
0.041
a
0.035
a
0.116
a
0.042
a
0.986
b
0.135
b
0.678
b
Data in parentheses are percentages. SPC: sporadic prostate can-
cer, NSPC: non-sporadic prostate cancer, PSA: prostate-specific 
antigen, 
a: Wilcoxon test, 
b: chi-square with Fisher’s exact test 
PCa. We also evaluated the relation between socio-
economic status and the incidence of nonsporadic prostate 
cancer (NSPC). 
MATERIALS AND METHODS
We collected data from all patients who were treated for 
PCa at our center between November 2009 and January 
2010. These patients were either newly diagnosed or were 
known to have PCa and were seen as outpatients during 
the study period. In-person interviews were conducted by 
trained male interviewers using standardized question-
naires. We observed 229 PCa patients during the study 
period. Eleven patients who did not know their genea-
logical data and were unable to answer related questions 
were excluded. We enrolled 218 patients in our study: 25 
patients (11.4%) with NSPC and 193 patients (88.6%) with 
sporadic prostate cancer (SPC). Among the NSPC patients, 
19 were diagnosed and treated at our hospital.
The family medical information collected included pedi-
gree, cancer history, medical history, and social and demo-
graphic factors. Clinical information was obtained from 
193 SPC and 19 NSPC patients, including Gleason score, 
2005 TNM stage, serum prostate-specific antigen (PSA) 
level at diagnosis, primary treatment, and disease pro-
gression. 
Systematic genealogical analyses of probands were per-
formed by questionnaire to classify the patients into three 
epidemiologic categories of PCa according to Carter’s cri-
teria [6]: SPC; familial prostate cancer (FPC), which was 
PCa with an unpredictable clustering in families; and he-
reditary prostate cancer (HPC), which was PCa with a 
strong clustering pattern and early onset of PCa. FPC and 
HPC were defined as NSPC. All patients were also strati-
fied in three categories according to age at onset of PCa: 55 
years or less, 56 to 65 years, and 65 years or older.
Descriptive statistics were used for frequency estimates 
with exact 95% confidence intervals (CIs). Differences in 
PSA, clinical stage, and Gleason scores between the NSPC 
and SPC groups according to age were compared by using 
the Wilcoxon test. Fisher’s exact test or Pearson’s chi- 
square test were used to compare categorical variables. 
RESULTS
In our sample of 218 patients with PCa, 1 sample was from 
an HPC family (three patients in a family, 1.4%) and 11 
were from FPC families (2 patients in each family, total of 
22 patients, 10.1%) according to Carter’s criteria. Eight 
SPC patients (9.3%) and six NSPC patients (24%) were di-
agnosed at 55 years or younger (p=0.02). In our study sam-
ple, the youngest NSPC patient was 46 years old and the 
youngest SPC patient was 51 years old. Of 18 patients who 
were newly diagnosed with PCa during the study period, 
4 patients were diagnosed with NSPC and 14 patients were 
diagnosed with SPC. 
The characteristics shared between the SPC and NSPC 
groups are given in Table 1. The mean age at diagnosis was 
68.0 years for all patients. The mean age at diagnosis of 
NSPC patients (64.6±4.8 years) was significantly earlier 
(p=0.035) than that of SPC patients (69.1±3.4 years). SPC 
patients had larger waist circumferences than did NSPC 
patients (p=0.041). Whereas biopsy Gleason scores were 
not significantly different between the two groups, PSA 
levels in the NSPC group were significantly higher than in 
the SPC group (7.2±.3.2 vs. 6.3±4.9 ng/ml, p=0.042). Among 
the patients who underwent surgery (149 SPC and 13 
NSPC patients) as the primary treatment, there were no 
significant differences in pathological stage or Gleason 
grade between the two groups. 
Table 2 shows the socioeconomic status of the SPC and 
NSPC patients. There was no significant difference be-
tween the NSPC and SPC patients in the duration of 
smoking. There were no associations between marital sta-
tus, monthly income, education level, smoking, alcohol in-
take, or occupational physical activity and risk of NSPC at 
diagnosis.
DISCUSSION
A positive family history is one of the strongest epidemio-
logic risk factors for PCa [7,8]. In general, familial cancer 
accounts for 15% to 20% of all PCa, and hereditary cancer 
for 5% to 10% [5]. In our Korean sample, the incidence of Korean J Urol 2011;52:9-12
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TABLE 2. Socioeconomic status of SPC and NSPC patients
SPC NSPC p-value
Marital status 
Married/living together 
Divorced, separated, or 
widowed
Single
Monthly income, US $ (₩)
＜1,500 (1,650,000)
＞1,500 (1,650,000)
Education level
＜High school 
High school graduate 
＞High school 
Smoking at diagnosis 
Yes 
No
Alcohol intake at 
diagnosis
＞30 g/d
＜30 g/d
Mean (SEM) duration of 
smoking, pack years
Occupational physical 
activity at diagnosis
Very active 
Moderately active 
Inactive 
181
137 (75.6)
  42 (23.2)
  2 (1.1)
135 (74.6)
  46 (25.4)
  29 (16.0)
  77 (42.6)
  75 (41.4)
139 (76.8)
  42 (23.2)
  83 (45.9)
  98 (54.1)
27 (1.6)
  63 (34.8)
  92 (50.8)
  26 (14.4)
17
12 (70.6)
  4 (23.5)
1 (5.9)
12 (70.6)
  5 (29.4)
  3 (17.6)
  9 (53.0)
  5 (29.4)
12 (70.6)
  5 (29.4)
  6 (35.3)
11 (64.7)
18 (2.5)
10 (58.8)
  5 (29.4)
  2 (11.8)
0.336
a
0.773
a
0.661
a
0.558
a
0.454
a
0.072
a
0.118
a
Data in parentheses are percentages except for smoking. SPC: 
sporadic prostate cancer, NSPC: non-sporadic prostate cancer, 
a:
chi-square with Fisher’s exact test
FPC was 10.1% and that of HPC was 1.4%, which is rela-
tively low compared with the incidences of FPC and HPC 
in Western men. However, we were unable to distinguish 
whether this low familial incidence of NSPC in Korea was 
“real” or was simply an artifact of “unknown” deaths of the 
first generation in the pre-PSA era (PSA-unavailable era). 
The incidence of PCa has rapidly increased over the past 
10 years in East Asia, including Korea. PCa is currently the 
fifth most common cancer in Korean men and resulted in 
1,168 deaths in 2007 [9]. The results of our pilot study sug-
gest that future studies to elucidate the epidemiology of 
NSPC in Korea are warranted. 
In the present study, we found no significant differences 
in tumor stage or Gleason grade between SPC and NSPC 
patients. However, we did not calculate the survival rates 
of SPC and NSPC patients. Many recent studies have sug-
gested that there are no differences in the aggressiveness 
of PCa between SPC and FPC [10-12]. Kupelian et al re-
ported that there were no associations between the pres-
ence of a family history of PCa and any demographic, clin-
ical, or treatment factors, except age [10]. Lee et al per-
formed a retrospective analysis of 557 men with localized 
PCa who were treated by radical prostatectomy and 
showed that the NSPC patients were younger at the time 
of surgery than were the SPC patients [11]. Roemeling et 
al analyzed the characteristics of NSPC by use of the 
screening arm of the Rotterdam section of the European 
Randomized Study of Screening for Prostate Cancer and 
reported that the cancer detection rate in 1,364 men with 
a positive family history was 7.7% (106 cancers in 1,364 
screened men with a positive family history) in the preva-
lence screen, whereas the positive predictive value of biop-
sies was 32.2% (154 cancers in 532 biopsies) [12]. In 12,803 
sporadic cases, the detection rate was 4.7% and the positive 
predictive value was 23.6% (p=0.0001 and 0.003, RR 1.63). 
However, there were no clinicopathological differences be-
tween the groups. In the present study, patients with a pos-
itive family history presented at a younger age (69.1 vs. 
64.6 years) despite similar socioeconomic status between 
the SPC and NSPC patients. Our results were similar to 
those of previous studies. In a younger subgroup of pa-
tients, positive family history is more likely to be indicative 
of genetic predisposition, as suggested by the results of 
studies showing that loci of PCa susceptibility genes, such 
as PCa and HPC, are associated with earlier age at the time 
of diagnosis [13-15]. Another plausible hypothesis is that 
our patients were screened at earlier ages because men 
with positive family histories are known to be at a higher 
risk of developing PCa. Thus, men with close relatives af-
fected by PCa may participate in screening more often or 
earlier. 
Interestingly, we observed that body mass index (BMI) 
was lower in the NSPC patients than in the SPC patients, 
although this difference was not significant. However, the 
waist circumference of the NSPC patients was sig-
nificantly lower than that of the SPC patients. Even though 
the role of obesity as a risk factor for PCa remains unclear, 
body size is one of several factors hypothesized to be related 
to PCa [16,17]. In addition, the role of obesity across differ-
ent populations has been suggested by several epidemio-
logic and anthropometric studies [17,18]. However, there 
are few reports regarding whether BMI or waist circum-
ference influences the incidence of PCa in East Asian men, 
who are relatively slim according to Western criteria. Our 
results suggest that factors other than body mass might 
contribute to the occurrence and progression of NSPC. 
Moreover, a recent study showed that visceral adipose tis-
sue is strongly associated with adverse pathologic features 
in patients with localized PCa, including higher Gleason 
score and PCa risk groups [19]. Concerning this result, we 
believe that abdominal circumference might be a more im-
portant factor associated with PCa aggressiveness than 
generalized adiposity deposition as measured by BMI. 
　Valeri et al reported that the proportion of relatives with 
PSA greater than 4 ng/ml and PCa detection was not sig-
nificantly different according to familial status (sporadic 
or nonsporadic) [20]. However, our results differed. This 
may be because the study subjects had different ethnicity 
and eating habits. However, we believe that further studies 
are needed. 
There are several limitations to our study. First, this was Korean J Urol 2011;52:9-12
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a cross-sectional pilot study, and we did not collect data re-
garding differences in long-term survival between SPC 
and NSPC patients. Second, our sample of NSPC patients 
was small, which imposed limitations on statistical power. 
Our results suggest that larger population-based studies 
are warranted. In addition, to improve the identification 
of HPC and to clarify its clinical importance, it is necessary 
to study its genetic characteristics in depth. These include 
performing linkage studies to better define high-pene-
trance PCa susceptibility genes, large association studies 
to clarify the role of low-penetrance polymorphic alleles, 
and gene expression profile analyses to compare HPC 
forms with SPC forms. 
CONCLUSIONS
In this pilot study, we confirmed that in Korea, NSPC pa-
tients are diagnosed at an earlier age than are SPC pa-
tients, even though the incidence of NSPC is lower than in 
Western men. Our analyses of the relations between family 
history and socioeconomic status, preoperative PSA, biop-
sy Gleason score, pathological stage, and pathologic 
Gleason grade did not reveal any significant differences be-
tween SPC and NSPC patients. Our results suggest that 
studies with a long-term follow-up and large samples of 
East Asian male NSPC patients are warranted. 
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